Open Nav

Please submit your session questions in advance at

Mark A. Demitrack



Mark A. Demitrack, MD, joined Trevena as SVP & CMO in May 2018. He has over 30 years of neuroscience research experience in academia & industry. Dr. Demitrack served as CMO of Neuronetics, where he led the clinical development program for the NeuroStar System. Dr. Demitrack was Medical Director at Lilly where he led the development & NDA submission for duloxetine (Cymbalta). Dr. Demitrack was on the Psychiatry faculty at the University of Michigan Medical School, where he received federal grant funding in clinical research investigations studying the neuroendocrine pathophysiology of mood & related disorders. He received a BA in Physics from Columbia University & his MD from the Robert Wood Johnson Medical School. He completed psychiatry residency training at UCSF & a research fellowship at the NIMH. Dr. Demitrack is a Fellow of the American Psychiatric Association & a Member of the American College of Neuropsychopharmacology. He published over 100 articles, book chapters & reviews.

This speaker's sessions: